BioCryst bags $250M in a debt and royalty deal as the executive team preps a new drug launch for HAE
Three days after landing an FDA OK for their HAE drug berotralstat, BioCryst $BCRX now has some cash to see how far they can go in commercializing the therapy as Orladeyo.
The biotech reported Monday morning that they’ve inked a deal with Royalty Pharma that trades a chunk of their revenue from the drug for cash in hand. Royalty is paying out $125 million upfront, with a $200 million credit facility from Athyrium Capital Management that is being tapped for $125 million right off the bat. The rest will be held in reserve.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.